Abstract

The main objective of this study is to explore the clinical efficacy of sitagliptin combined with recombinant bovine basic fibroblast growth factor gel in the treatment of chronic diabetic foot ulcers and its effects on inflammatory factors. 116 patients with chronic diabetic foot ulcers were selected, in which 58 patients were treated with routine treatment and set as the control group. While the remaining 58 patients were treated with sitagliptin+recombinant bovine basic fibroblast growth factor gel on the basis of the control group and set as the combined group. The efficacy and various clinical therapeutic indexes were comparatively analyzed. The combined group showed higher efficacy than the control group after treatment, with smaller ulcer area and shorter ulcer wound healing time. In addition, the granulation tissue formation time and granulation tissue coverage were more significantly increased in the combined group compared with the control group, while the granulation tissue growth thickness was statistically reduced. Moreover, the serum high-sensitivity C-reactive protein and interleukin-6 levels were significantly reduced in the combined group, and the quality of life was obviously improved. Sitagliptin+recombinant bovine basic fibroblast growth factor gel is highly effective in the treatment of chronic diabetic foot ulcers and is a feasible clinical treatment scheme for the disease.